Physician profile
Skye Anthony Nehs
NPI 1740515097
$911.75
in general payments reported to CMS, 2019-2025
12 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.20 · 2022: $187 · 2023: $250 · 2024: $194 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $246.43 | 2021-2024 | Versacross Access Solution |
| Astrazeneca Pharmaceuticals LP | $129.45 | 2022-2024 | Brilinta, Lokelma |
| Novartis Pharmaceuticals Corporation | $109.95 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.06 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $85.77 | 2023-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $51.03 | 2025 | |
| Pfizer INC. | $41.56 | 2023 | |
| Amgen INC. | $40.18 | 2021-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $30.96 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $28.31 | 2025 | |
| Abiomed | $24.30 | 2025 | |
| Esperion Therapeutics, INC. | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skye Nehs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.